Table 1.
Summary of data obtained within 24 h of ED presentation in 340 patients with confirmed COVID-19
| Total no. | 340 |
| RT-PCR, positive initial results/total no. (%) | 313/340 (92%) |
| Age | |
| Median [IQR], year | 68 [57–76] |
| Distribution, no./total no. (%) | |
| 18–59 year | 101/340 (30%) |
| 60–69 year | 86/340 (25%) |
| 70–79 year | 96/340 (28%) |
| ≥ 80 year | 57/340 (17%) |
| Gender, F, no./total no. (%) | 88/340 (26%) |
| Smoking history, no./total no. (%) | |
| Never smoked | 102/165 (62%) |
| Former smoker | 54/165 (33%) |
| Current smoker | 9/165 (5%) |
| Comorbidities, no./total no. (%) | |
| Any | 167/215 (78%) |
| > 2 | 57/215 (27%) |
| Arterial hypertension | 162/340 (48%) |
| Cardiovascular disease** | 86/340 (25%) |
| Obesity*** | 50/215 (23%) |
| Diabetes | 54/340 (16%) |
| Dyslipidemia | 28/340 (8%) |
| COPD | 22/340 (6%) |
| Chronic renal failure | 12/340 (4%) |
| Neoplasia (active history) | 26/340 (8%) |
| Rheumatic pathology | 18/340 (5%) |
| Immunodepression | 20/340 (6%) |
| Epilepsy | 3/340 (1%) |
| Cirrhosis | 6/340 (2%) |
| Symptoms, no./total no. (%) | |
| Fever | 296/340 (87%) |
| Cough | 167/340 (49%) |
| Dyspnea | 224/340 (66%) |
| Pharyngodynia | 9/340 (3%) |
| Asthenia | 77/340 (23%) |
| Anorexia | 18/340 (5%) |
| Myalgia | 12/340 (4%) |
| Diarrhea | 19/340 (6%) |
| Nausea | 15/340 (4%) |
| Vomit | 16/340 (5%) |
| Dizziness | 18/340 (5%) |
| Abdominal pain | 6/340 (2%) |
| Chest pain | 12/340 (4%) |
| Duration of symptoms, no. with data | 332 |
| Median [IQR], days | 7 [5–10] |
| Laboratory data | |
| SpO2*, no. with data | 277 |
| Median [IQR], % | 90 [86–94] |
| PaO2/FiO2 ratio, no. with data | 258 |
| Median [IQR] | 238 [143–285] |
| Distribution, no./total no. | |
| < 100, severe ARDS | 41/258 (16%) |
| 100–200, moderate ARDS | 60/258 (23%) |
| 200–300, mild ARDS | 113/258 (44%) |
| > 300, normal | 44/258 (17%) |
| HB, g/dL | |
| Median [IQR] | 13.8 [12.5–14.9] |
| < 14, no./total no. (%) | 182/338 (54%) |
| > 17, no./total no. (%) | 10/338 (3%) |
| WBC, /mm3 | |
| Median [IQR] | 6380 [4865–9412] |
| < 4000, no./total no. (%) | 45/338 (13%) |
| > 10000, no./total no. (%) | 66/338 (20%) |
| Neutrophils | |
| Median [IQR] (WBC %) | 78 [72–86] |
| Median [IQR] (/mm3) | 4999 [3428–7665] |
| < 2000, no./total no. (%) | 16/287 (6%) |
| > 6700, no./total no. (%) | 89/287 (31%) |
| Lymphocytes | |
| Median [IQR] (WBC %) | 13 [8–18] |
| Median [IQR] (/mm3) | 805 [570–1088] |
| < 1000, no./total no. (%) | 131/190 (69%) |
| Monocytes | |
| Median [IQR] (WBC %) | 6[4–8] |
| Median [IQR] (/mm3) | 362 [245–554] |
| < 250, no./total no. (%) | 50/190 (26%) |
| > 800, no./total no. (%) | 16/190 (8%) |
| Eosinophils | |
| Median [IQR] (WBC %) | 0 [0–0.3] |
| Median [IQR] (/mm3) | 0 [0–14.2] |
| > 500, no./total no. (%) | 2/190 (1%) |
| Basophils | |
| Median [IQR] (WBC %) | 0.2 [0.1–0.3] |
| Median [IQR] (/mm3) | 11.9 [8.7–23.7] |
| > 100, no./total no. (%) | 3/190 (2%) |
| PLT, /mm3 | |
| Median [IQR] | 177,000 [140,000–226,000] |
| < 150,000, no./total no. (%) | 98/321 (31%) |
| > 400,000, no./total no. (%) | 8/321 (2%) |
| INR | |
| Median [IQR] | 1.07 [1.02–1.15] |
| > 1.25, no./total no. (%) | 34/279 (12%) |
| aPTT ratio | |
| Median [IQR] | 1.13 [1.02–1.26] |
| > 1.25, no./total no. (%) | 86/306 (28%) |
| AST, U/L | |
| Median [IQR] | 52 [37–77] |
| > 40, no./total no. (%) | 215/331 (65%) |
| ALT, U/L | |
| Median [IQR] | 39 [26–60] |
| > 40, no./total no. (%) | 149/335 (44%) |
| Creatinine, mg/dL | |
| Median [IQR] | 0.93 [0.77–1.23] |
| > 1.30, no./total no. (%) | 76/337 (23%) |
| Urea, mg/dL | |
| Median [IQR] | 43 [33–65] |
| > 50, no./total no. (%) | 109/285 (38%) |
| LDH, U/L | |
| Median [IQR] | 404 [314–551] |
| ≥ 250, no./total no. (%) | 278/306 (91%) |
| CRP, mg/dL | |
| Median [IQR] | 12 [6–18] |
| ≥ 1, no./total no. (%) | 323/333 (97%) |
| Fibrinogen, g/dL | |
| Median [IQR] | 0.63 [0.52–0.73] |
| < 0.150, no./total no. (%) | 0/63 (0%) |
| > 0.400, no./total no. (%) | 59/63 (94%) |
| Na, mEq/L | |
| Median [IQR] | 138 [136–140] |
| < 136, no./total no. (%) | 78/335 (23%) |
| > 145, no./total no. (%) | 9/335 (3%) |
| K, mEq/L | |
| Median [IQR] | 3.9 [3.6–4.3] |
| < 3.5, no./total no. (%) | 55/331 (17%) |
| > 5, no./total no. (%) | 19/331 (6%) |
| Cl, mEq/L | |
| Median [IQR] | 101 [98–104] |
| < 98, no./total no. (%) | 47/243 (19%) |
| > 107, no./total no. (%) | 18/243 (7%) |
*SpO2 values are reported only in cases with FiO2 = 0.21. **Including coronary heart disease, cerebrovascular disease, heart failure, and peripheral vascular disease. ***Defined as BMI ≥ 30. Data are reported as median [IQR] (continuous/numerical variables) or number (%) (binary variables). ARDS, acute respiratory distress syndrome; ED, emergency department; COVID-19, coronavirus disease 2019; RT-PCR, real-time reverse transcriptase–polymerase chain reaction; COPD, chronic obstructive pulmonary disease; PaO2/FiO2 ratio, ratio of partial pressure of oxygen to fraction of inspired oxygen; HB, hemoglobin; WBC, white blood cells; PLT, platelets; INR, international normalized ratio; aPTT ratio, activated partial thromboplastin time ratio; AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; CRP, C-reactive protein; SpO2, oxygen saturation; FiO2, fraction of inspired oxygen; IQR, interquartile range